Estimates and Recommendations for Eli Lilly on August 30



Wall Street analysts’ estimates

Wall Street analysts expect Eli Lilly and Company (LLY) to report a 6.3% rise in YoY revenue to ~$24.3 billion in 2018 compared to $22.9 billion in 2017.

Its EPS are expected to be $5.47 in 2018. Analysts expect the company’s net income margin to expand to 23.8% in 2018 compared to 21.3% in 2017.

The chart above compares changes in analysts’ recommendations for Eli Lilly and Company since January.

Article continues below advertisement

2018 guidance

Eli Lilly expects its revenue to be between $24.0 billion and $24.5 billion in 2018 driven by a favorable portfolio and higher collaboration revenue. The company expects its non-GAAP (generally accepted accounting principles) gross profit margin to rise to ~76% due to the favorable impact of foreign exchange. Its non-GAAP EPS are expected to be between $5.40 and $5.50 in 2018.

Analysts’ ratings

Eli Lilly’s stock price has risen nearly 34.1% in the last 12 months and nearly 24.7% in 2018 year-to-date. Analysts expect that the stock to fall 7.5% over the next 12 months. Their recommendations show a 12-month target price of $97.47 per share for the stock compared to its price of $105.33 per share on August 29.

As of August 30, 16 analysts are tracking Eli Lilly. Of these, three analysts have recommended “strong buys,” five have recommended “buys,” and eight have recommended “holds.” No analysts have recommended “sells” on the stock. The consensus rating for Eli Lilly stands at 2.31, which represents a moderate “buy” for long-term growth investors as well as value investors.

The Health Care Select Sector SPDR ETF (XLV) holds 2.8% of its total investments in Eli Lilly, 5.1% in Merck & Co. (MRK), 6.7% in Pfizer (PFE), and 3.7% in Amgen (AMGN).


More From Market Realist